Document Detail

Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
MedLine Citation:
PMID:  3813189     Owner:  NLM     Status:  MEDLINE    
Vasodilator therapy for pulmonary hypertension ideally should cause a proportionately greater reduction of resistance in the pulmonary vascular bed than in the systemic circulation. This should limit the occurrence of systemic hypotension, which can complicate the use of most vasodilator drugs. Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone. We investigated and compared the short-term effects of Urapidil and hydralazine in 10 patients suffering varying degrees of pulmonary hypertension. Each patient received either 0.35 mg/kg hydralazine or 0.75 mg/kg Urapidil intravenously on 2 sequential days in a randomized order. The main effect of Urapidil was to decrease the mean pulmonary artery pressure in all 10 patients from 44 +/- 4 to 37 +/- 3.5 mm Hg (p less than 0.001). After Urapidil infusion, the mean decrease of resistance in the pulmonary vascular bed (32%) exceeded that in the systemic circulation (25%). In contrast, pulmonary artery pressure remained unchanged with hydralazine, and predominant systemic vasodilation occurred: systemic vascular resistance decreased by 45%, whereas pulmonary vascular resistance decreased by 25%. Hydralazine markedly increased the cardiac index and induced tachycardia. Urapidil maintained the heart rate nearly constant and only slightly increased the cardiac index, thereby fostering the diastolic emptying of the pulmonary circulation. No significant change in arterial oxygenation occurred with either drug, although arterial oxygen partial pressure tended to increase with hydralazine. Urapidil may be a promising drug in the treatment of patients with pulmonary hypertension.
S Adnot; C Defouilloy; C Brun-Buisson; F Abrouk; J Piquet; F Lemaire
Related Documents :
7365689 - Comparative effects of thromboxane b2 on the canine and feline pulmonary vascular bed.
7614719 - Pulmonary microvascular permeability. responses to high vascular pressure after inducti...
10147919 - What role for echocardiography in primary pulmonary hypertension? new ultrasound method...
6776599 - Cardiopulmonary consequences of decompression stress.
1328139 - Differential effects of general anesthesia on cgmp-mediated pulmonary vasodilation.
1153409 - Comparison of the effects of prostaglandins f1alpha, f2alpha, f1beta, and f2beta on the...
2561139 - Brain corticosteroid receptors and regulation of arterial blood pressure.
10564139 - Inhaled nitric oxide inhibits nos activity in lambs: potential mechanism for rebound pu...
14693309 - Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American review of respiratory disease     Volume:  135     ISSN:  0003-0805     ISO Abbreviation:  Am. Rev. Respir. Dis.     Publication Date:  1987 Feb 
Date Detail:
Created Date:  1987-03-11     Completed Date:  1987-03-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370523     Medline TA:  Am Rev Respir Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  288-93     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / drug effects
Cardiac Output / drug effects
Hemodynamics / drug effects*
Hydralazine / therapeutic use*
Hypertension, Pulmonary / drug therapy*,  physiopathology
Middle Aged
Piperazines / therapeutic use*
Pulmonary Artery / drug effects
Vascular Resistance / drug effects
Reg. No./Substance:
0/Piperazines; 34661-75-1/urapidil; 86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chest pain, shock, and pneumomediastinum in a previously healthy 56-year-old man.
Next Document:  Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen productio...